128 related articles for article (PubMed ID: 17237269)
41. Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors.
Yamamoto N; Yamada Y; Fujiwara Y; Yamada K; Fujisaka Y; Shimizu T; Tamura T
Jpn J Clin Oncol; 2009 Apr; 39(4):260-6. PubMed ID: 19261664
[TBL] [Abstract][Full Text] [Related]
42. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
43. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.
O'Brien NA; Browne BC; Chow L; Wang Y; Ginther C; Arboleda J; Duffy MJ; Crown J; O'Donovan N; Slamon DJ
Mol Cancer Ther; 2010 Jun; 9(6):1489-502. PubMed ID: 20501798
[TBL] [Abstract][Full Text] [Related]
44. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer.
Macleod K; Mullen P; Sewell J; Rabiasz G; Lawrie S; Miller E; Smyth JF; Langdon SP
Cancer Res; 2005 Aug; 65(15):6789-800. PubMed ID: 16061661
[TBL] [Abstract][Full Text] [Related]
45. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
[TBL] [Abstract][Full Text] [Related]
46. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Kim J; Lee J; Kim C; Choi J; Kim A
Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
[TBL] [Abstract][Full Text] [Related]
47. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
Kalous O; Conklin D; Desai AJ; O'Brien NA; Ginther C; Anderson L; Cohen DJ; Britten CD; Taylor I; Christensen JG; Slamon DJ; Finn RS
Mol Cancer Ther; 2012 Sep; 11(9):1978-87. PubMed ID: 22761403
[TBL] [Abstract][Full Text] [Related]
48. Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase.
Gründker C; Völker P; Emons G
Endocrinology; 2001 Jun; 142(6):2369-80. PubMed ID: 11356684
[TBL] [Abstract][Full Text] [Related]
49. Role of TGF alpha stimulation of the ERK, PI3 kinase and PLC gamma pathways in ovarian cancer growth and migration.
Sewell JM; Smyth JF; Langdon SP
Exp Cell Res; 2005 Mar; 304(1):305-16. PubMed ID: 15707595
[TBL] [Abstract][Full Text] [Related]
50. Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation.
Brockhoff G; Heckel B; Schmidt-Bruecken E; Plander M; Hofstaedter F; Vollmann A; Diermeier S
Cell Prolif; 2007 Aug; 40(4):488-507. PubMed ID: 17635517
[TBL] [Abstract][Full Text] [Related]
51. A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells.
Khalil HS; Langdon SP; Goltsov A; Soininen T; Harrison DJ; Bown J; Deeni YY
Oncotarget; 2016 Nov; 7(46):75874-75901. PubMed ID: 27713148
[TBL] [Abstract][Full Text] [Related]
52. Enhancement of paclitaxel-induced apoptosis in HER2-overexpressing human breast cancer cells by a pertuzumab mimetic peptide, HRAP.
Nakajima H; Mizuta N; Sakaguchi K; Fujiwara I; Yoshimori A; Magae J; Tanuma S
J Biosci Bioeng; 2010 Aug; 110(2):250-3. PubMed ID: 20547325
[TBL] [Abstract][Full Text] [Related]
53. Sensitization of breast cancer cells to radiation by trastuzumab.
Liang K; Lu Y; Jin W; Ang KK; Milas L; Fan Z
Mol Cancer Ther; 2003 Nov; 2(11):1113-20. PubMed ID: 14617784
[TBL] [Abstract][Full Text] [Related]
54. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.
Yoshida T; Okamoto I; Okabe T; Iwasa T; Satoh T; Nishio K; Fukuoka M; Nakagawa K
Int J Cancer; 2008 Apr; 122(7):1530-8. PubMed ID: 18033688
[TBL] [Abstract][Full Text] [Related]
55. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models.
Yamashita-Kashima Y; Iijima S; Yorozu K; Furugaki K; Kurasawa M; Ohta M; Fujimoto-Ouchi K
Clin Cancer Res; 2011 Aug; 17(15):5060-70. PubMed ID: 21700765
[TBL] [Abstract][Full Text] [Related]
56. Her2 crosstalks with TrkA in a subset of prostate cancer cells: rationale for a guided dual treatment.
Festuccia C; Gravina GL; Muzi P; Millimaggi D; Dolo V; Vicentini C; Ficorella C; Ricevuto E; Bologna M
Prostate; 2009 Mar; 69(4):337-45. PubMed ID: 19016477
[TBL] [Abstract][Full Text] [Related]
57. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab.
Adams CW; Allison DE; Flagella K; Presta L; Clarke J; Dybdal N; McKeever K; Sliwkowski MX
Cancer Immunol Immunother; 2006 Jun; 55(6):717-27. PubMed ID: 16151804
[TBL] [Abstract][Full Text] [Related]
58. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.
Baselga J; Swain SM
Clin Breast Cancer; 2010 Dec; 10(6):489-91. PubMed ID: 21147694
[TBL] [Abstract][Full Text] [Related]
59. Neuregulin expression, function, and signaling in human ovarian cancer cells.
Gilmour LM; Macleod KG; McCaig A; Sewell JM; Gullick WJ; Smyth JF; Langdon SP
Clin Cancer Res; 2002 Dec; 8(12):3933-42. PubMed ID: 12473609
[TBL] [Abstract][Full Text] [Related]
60. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.
Baselga J; Cortés J; Im SA; Clark E; Ross G; Kiermaier A; Swain SM
J Clin Oncol; 2014 Nov; 32(33):3753-61. PubMed ID: 25332247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
